(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 7.1MM | -4% |
Gross Profit | 6.5MM | - |
Cost Of Revenue | 586K | -7% |
Operating Income | -106.3MM | +5% |
Operating Expenses | 112.8MM | - |
Net Income | -95.9MM | +5% |
R&D | 77.5MM | -5% |
G&A | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024, at 10:00 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay
Agios Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 84 to 91 Monday. When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. Is Agios Pharmaceuticals Stock A Buy?
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, at 2:10 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the we
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call Transcript February 15, 2024 Agios Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to the Agios Fourth Quarter 2023 Earnings Conference Call. At this time, all […]
Investors in Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) had a good week, as its shares rose 5.4% to close at US$26.51...
One thing we could say about the analysts on Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) - they aren't optimistic...
Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.
Q4 2023 Agios Pharmaceuticals Inc Earnings Call
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -4.88% and 9.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?